Last Week Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings

May 17, 2018 - By Marcos Kline

Regulus Therapeutics Inc. (NASDAQ:RGLS) Corporate Logo
Big Money Sentiment decreased to 1.16 in 2017 Q4. It has change of 0.19, from 2017Q3’s 1.35. The ratio fall due to Regulus Therapeutics Inc. positioning: 7 sold and 12 reduced. 10 funds took holdings and 12 increased holdings. Investors holded 58.85 million in 2017Q3 but now own 53.17 million shares or 9.64% less.
Renaissance Technology Limited Liability Corporation holds 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS) or 137,589 shs. D E Shaw And Inc invested 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Deutsche National Bank & Trust Ag holds 0% of its capital in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 98 shs. Point72 Asset Mgmt Limited Partnership holds 0.01% or 1.14M shs in its capital. Manufacturers Life Insur The accumulated 6,057 shs. Susquehanna Gru Llp holds 0% or 32,631 shs. Retail Bank Of New York Mellon Corp holds 0% or 36,752 shs in its capital. Moreover, Blackrock has 0% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS). Geode Cap Mngmt Ltd accumulated 483,951 shs. Hightower Advisors Lc invested in 21,200 shs or 0% of the stock. Royal Fincl Bank Of Canada holds 0% of its capital in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 109,607 shs. Meeder Asset Management has 8,981 shs. Moreover, Macquarie Group Inc Limited has 0% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS). Mariner Wealth Advsrs Limited Liability holds 0% or 37,400 shs. State Street owns 47,869 shs.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings Coverage

Total analysts of 5 have positions in Regulus (NASDAQ:RGLS) as follows: 2 rated it a “Buy”, 0 with “Sell” and 3 with “Hold”. The positive are 40%. Since December 11, 2017 according to StockzIntelligence Inc Regulus has 8 analyst reports. On Tuesday, March 27 FBR Capital initiated Regulus Therapeutics Inc. (NASDAQ:RGLS) rating. FBR Capital has “Hold” rating and $100 target. On Wednesday, December 20 Wedbush maintained the shares of RGLS in report with “Buy” rating. On Monday, December 11 Wedbush maintained Regulus Therapeutics Inc. (NASDAQ:RGLS) with “Buy” rating. On Thursday, March 8 BMO Capital Markets maintained Regulus Therapeutics Inc. (NASDAQ:RGLS) rating. BMO Capital Markets has “Market Perform” rating and $1.37 target. On Monday, March 12 the firm has “Buy” rating given by Wedbush. The stock rating was maintained by Wedbush with “Buy” on Thursday, February 8. Listed here are Regulus Therapeutics Inc. (NASDAQ:RGLS) PTs and latest ratings.

28/03/2018 Broker: B. Riley & Co Rating: Neutral New Target: $1 Initiates Coverage On
27/03/2018 Broker: FBR Capital Rating: Hold New Target: $1.0000 Initiate
12/03/2018 Broker: Wedbush Rating: Buy New Target: $3.0 Maintain
08/03/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $1 New Target: $1.37 Maintain
08/02/2018 Broker: Wedbush Rating: Buy New Target: $4.0 Maintain
05/01/2018 Broker: Leerink Swann Rating: Outperform New Target: $2 Initiates Coverage On
20/12/2017 Broker: Wedbush Rating: Buy New Target: $4.0 Maintain
11/12/2017 Broker: Wedbush Rating: Buy New Target: $4.0 Maintain

RGLS touched $0.71 during the last trading session after $0 change.Since May 17, 2017 it’s 52.76% down thus downtrending. RGLS underperformed the S&P 500 by 64.31%.

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States.The company has $74.07 million market cap. The firm uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides.Currently it has negative earnings. The Company’s clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease.

Another two news for Regulus Therapeutics Inc. (NASDAQ:RGLS) were recently released by: Globenewswire.com on May 17, 2018 with title “Report: Developing Opportunities within Regulus Therapeutics, Airgain, Michael Kors, Heritage Insurance, CDK Global …”. The other Seekingalpha.com‘s article was titled “Regulus Therapeutics’ (RGLS) CEO Joseph Hagan on Q1 2018 Results – Earnings Call Transcript” and released on May 11, 2018.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.